BRIEF-Protagonist Announces Plans To Initiate A Global Phase 3 Study For Rusfertide In Polycythemia Vera
BRIEF-Protagonist Announces Plans To Initiate A Global Phase 3 Study For Rusfertide In Polycythemia Vera
* PROTAGONIST ANNOUNCES PLANS TO INITIATE A GLOBAL PHASE 3 STUDY FOR RUSFERTIDE IN POLYCYTHEMIA VERA FOLLOWING INTERACTIONS WITH THE U.S. FOOD & DRUG ADMINISTRATION AND THE EUROPEAN MEDICINES AGENCY
* PROTAGONIST - END-OF-PHASE-2 MEETING WITH FDA, & WRITTEN COMMENTS FROM EMA, SUPPORT ADVANCEMENT OF CLINICAL DEVELOPMENT PLAN FOR RUSFERTIDE IN PV
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
March 22 (Reuters) - Protagonist Therapeutics Inc :
* PROTAGONIST ANNOUNCES PLANS TO INITIATE A GLOBAL PHASE 3 STUDY FOR RUSFERTIDE IN POLYCYTHEMIA VERA FOLLOWING INTERACTIONS WITH THE U.S. FOOD & DRUG ADMINISTRATION AND THE EUROPEAN MEDICINES AGENCY
* PROTAGONIST - END-OF-PHASE-2 MEETING WITH FDA, & WRITTEN COMMENTS FROM EMA, SUPPORT ADVANCEMENT OF CLINICAL DEVELOPMENT PLAN FOR RUSFERTIDE IN PV
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透3月22日電-主角治療公司：*Protagant宣佈計劃在與美國食品和藥物管理局(FDA)和歐洲藥品管理局(European Drug Agency)互動後，啟動RUSFERTIDE治療真性紅細胞增多症的全球3期研究*主角-與FDA的第二階段結束會議，以及EMA的書面意見，支持推進RUSFERTIDE在PV中的臨牀開發計劃Eikon的源文本：進一步的公司報道：(Reurs.Briefs@thomsonreurs.com；)
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧